Method of reducing formation of etanercept aggregates or fragments
The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.
1. A method of reducing formation of etanercept aggregates or fragments in a composition comprising combining about 50 mg/mL etanercept with about 1% (w/v) sucrose, 0.26% (w/v) to 2% (w/v) mannitol or lysine; and less than 50 mM NaCl in an aqueous pharmaceutical composition having a pH of about 6.0 to 6.6, wherein the aqueous pharmaceutical composition comprises a citrate buffer, the composition is free of arginine and cysteine, the composition has at least 90 wt. % correctly folded etanercept, the composition has less than 1 wt. % aggregates of etanercept, and wherein the combination of said sucrose and said mannitol or lysine stabilizes said etanercept in said aqueous pharmaceutical composition, wherein the composition has an osmolality from about 180 to about 420 mOsM, and wherein the etanercept is prepared by a mixed mode cation exchange chromatography and mixed mode anion exchange chromatography method resulting in less than 1 wt % aggregates of etanercept.
2. The method of claim 1 , wherein the stable aqueous etanercept composition has at M 3 or T 2 or T 4 no more than, on average, about 10,000 subvisible particles per mL having a size greater than 5 μm.
3. The method of claim 1 , wherein the aqueous pharmaceutical composition elicits long term storage stability as characterized by at least one of:
SEC analysis at M 3 or T 4 at 40° C. of: monomer content greater than 90 wt. %;
aggregate content of less than 1 wt %; and fragment 3 content less than 5 wt. %; and HIC analysis at M 3 or T 2 or T 4 wherein the amount of the composition represented by peak 1 of the HIC chromatogram is less than about 3 wt. %.
4. The method of claim 1 , wherein the aqueous pharmaceutical composition is characterized by SEC analysis at M 3 or T 2 or T 4 in which fragment 3 content is less than about 10 wt. %.
5. The method of claim 1 , wherein the stable aqueous etanercept composition elicits long term storage stability as characterized by: an HIC analysis at M 3 or T 2 or T 4 wherein the amount of the composition represented by peak 2 of the HIC chromatogram is greater than or equal to about 95 wt. %; and wherein, if peak 3 is present on the HIC chromatogram, the amount of the composition represented by peak 3 is less than or equal to about 3 wt. %.
6. The method of claim 1 , further comprising adding about 10 mM to about 200 mM of a tonicity modifier selected from potassium chloride, sodium citrate, or a combination thereof.
7. A method of treating a patient in need of treatment with etanercept, comprising administering to said patient an aqueous pharmaceutical composition made according to the method of claim 1 wherein the administrating comprises injecting the aqueous pharmaceutical composition subcutaneously or intramuscularly.
8. The method of claim 7 , comprising administering 25-100 mg etanercept per dose to the subject.
9. A method of treating a subject in need thereof for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Wegener's disease, Crohn's disease, chronic obstructive pulmonary disease (COPD), Hepatitis C, endometriosis, asthma, cachexia, psoriasis, or atopic dermatitis comprising administering to the subject the aqueous pharmaceutical composition made according to the method of claim 1 .
10. The method of claim 9 , comprising administering 25-100 mg etanercept per dose to the subject.
11. The method of claim 9 , wherein the administering comprises injecting the aqueous pharmaceutical composition subcutaneously or intramuscularly.
12. A vial, syringe, or injector pen containing a stable aqueous etanercept composition comprising about 50 mg/mL etanercept, about 1% (w/v) sucrose, 0.26% (w/v) to 2% (w/v) mannitol or lysine; an aqueous carrier wherein the aqueous carrier comprises a citrate buffer, the composition is free of arginine and cysteine, the composition has a pH of about 6.0 to 6.6, the composition has at least 90 wt. % correctly folded etanercept, the composition has less than 1 wt. % aggregates of etanercept, the composition has less than 50 mM NaCl, the composition has an osmolality from about 180 to about 420 mOsm, wherein the composition further comprises 10 mM to about 200 mM of a tonicity modifier selected from potassium chloride and sodium citrate, or a combination thereof, wherein the combination of said sucrose and said mannitol or lysine stabilizes said etanercept in said aqueous pharmaceutical composition, and wherein the etanercept is prepared by a mixed mode cation exchange chromatography and mixed mode anion exchange chromatography method resulting in less than 1 wt. % aggregates of etanercept.
13. The method of claim 1 , wherein the etanercept is at 50 mg/mL.
14. The method of claim 1 , wherein the sucrose is at 1% (w/v).
15. The method of claim 7 , wherein the etanercept is at 50 mg/mL.
16. The method of claim 7 , wherein the sucrose is at 1% (w/v).
17. The method of claim 9 , wherein the etanercept is at 50 mg/mL.
18. The method of claim 9 , wherein the sucrose is at 1% (w/v).
19. The vial, syringe or injector pen of claim 12 , wherein the etanercept is at 50 mg/mL.
20. The vial, syringe or injector pen of claim 12 , wherein the sucrose is at 1% (w/v).